|
|
MULTITUMOR CONFERENCE: Friday-Sunday, April 24-26, 2026, Orlando, Florida
Fifth Annual National General Medical Oncology SummitA Multitumor CME/MOC-, NCPD- and ACPE-Accredited Educational Conference Developed in Partnership with Florida Cancer Specialists & Research Institute
Dates
Friday to Sunday April 24 to 26, 2026 Location The Ritz-Carlton Orlando, Grande Lakes 4012 Central Florida Parkway Orlando, Florida Hotel Phone: (407) 206-2400 Meeting Room Plaza Ballroom – Lobby Level
Room Reservations
A special discounted room rate of $419 per night (plus applicable tax and discounted resort fee) is available to conference attendees at The Ritz-Carlton Orlando, Grande Lakes. Please see the Location tab for details. Note from the Moderator This coming April 24th marks the return of our annual National General Medical Oncology Summit. To add community perspectives, we are pleased to be partnering again with Florida Cancer Specialists & Research Institute for this one-of-a-kind offering that will span 3 days and feature a stellar multidisciplinary faculty panel of clinical investigators and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. The conference’s educational design and the topics that will be discussed offer interested clinicians access to the in-depth perspectives of some of the top minds in the field regarding significant new datasets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with cancer. We hope you will join us in sunny Florida for a learning experience unlike any other out there. FACULTY Acute Myeloid Leukemia Courtney D DiNardo, MD, MSCE Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas Additional faculty to be announced. Breast Cancer Adam M Brufsky, MD, PhD Professor of Medicine UPMC Hillman Cancer Center Department of Medicine University of Pittsburgh Pittsburgh, Pennsylvania Erika Hamilton, MD Chief Development Officer, Late Phase Director, Breast Cancer Research Program Sarah Cannon Research Institute SCRI Oncology Partners Nashville, Tennessee Additional faculty to be announced. Colorectal Cancer Kristen K Ciombor, MD, MSCI Associate Professor of Medicine Division of Hematology/Oncology Vanderbilt-Ingram Cancer Center Nashville, Tennessee John Strickler, MD Professor of Medicine Associate Director, Clinical Research – GI Co-Leader, Molecular Tumor Board Duke University Durham, North Carolina Gastroesophageal Cancers Samuel J Klempner, MD Program Director, Gastroesophageal Cancers Tobins Family Endowed Chair in Esophagogastric Cancer Massachusetts General Hospital Associate Professor, Harvard Medical School Boston, Massachusetts Additional faculty to be announced. Lung Cancer Zofia Piotrowska, MD, MHS Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts Additional faculty to be announced. Lymphoma Manali Kamdar, MD, MBBS Associate Professor Clinical Director of Lymphoma Services Morton and Sandra Saffer Endowed Chair in Hematology Research Division of Hematology, Hematologic Malignancies University of Colorado Cancer Center Aurora, Colorado Gilles Salles, MD, PhD Service Chief, Lymphoma Service Steven Greenberg Chair Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Additional faculty to be announced. Prostate Cancer Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, Utah Additional faculty to be announced. Relapsed/Refractory Multiple Myeloma Hans Lee, MD Director, Multiple Myeloma Research Sarah Cannon Research Institute Nashville, Tennessee Noopur Raje, MD Director, Center for Multiple Myeloma Rita Kelley Chair in Oncology Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts Urothelial Bladder Cancer Daniel P Petrylak, MD Professor of Internal Medicine (Medical Oncology) and Urology Yale School of Medicine New Haven, Connecticut Additional faculty to be announced. MODERATOR Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, GSK, Lilly, Merck, Natera Inc, and Revolution Medicines Inc. Friday to Sunday, April 24 to April 26, 2026 A detailed agenda and speaker information will be made available in the coming months. Times and schedule are subject to change. Preliminary Agenda (Eastern Time) Friday, April 24th 6:30 PM – 7:00 PM — Welcome Reception 7:00 PM – 9:00 PM — Keynote Session Saturday, April 25th 7:00 AM – 7:45 AM — Breakfast 7:45 AM – 12:30 PM — Morning General Session 12:30 PM – 1:15 PM — Lunch 1:15 PM – 5:30 PM — Afternoon General Session Sunday, April 26th 7:00 AM – 7:45 AM — Breakfast 7:45 AM – 12:15 PM — Morning General Session 12:15 PM – 1:00 PM — Lunch 1:00 PM – 3:30 PM — Afternoon General Session Target Audience CE Credit MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company. RESEARCH TO PRACTICE CME/NCPD/ACPE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters The Ritz-Carlton Orlando, Grande Lakes Meeting Room Room Reservations Instructions on how to secure hotel accommodations will be included in the confirmation email after you have completed registration. Room reservations must be made by Thursday, April 2, 2026. A limited number of rooms are available, and we encourage you to make your reservations early. After Thursday, April 2nd the hotel will offer the best rates based on room availability. Parking
Self-Parking: Not available at the hotel. Please Note: All parking rates are subject to change. Map
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.
In-Person Registration: This event is free of charge for practicing physicians, fellows, pharmacists, nurses and other healthcare providers actively caring for patients with cancer. At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel,* we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you. No fee is charged to attend the session virtually. In-Person Registration:
I am a practicing physician, fellow, nurse, pharmacist or other healthcare provider involved in the treatment of cancer. FREE IN-PERSON Registrationfor clinicians » STANDBY IN-PERSON Registration for other/industry professionals*
If you would like to stand by for participation in this event, please provide your contact information here. We will notify you if seats become available. Standby IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions and biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals (free of charge)
This event will be streamed via Zoom. Registration details for virtual attendance will be shared in the coming months. Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program. Meal service will be provided to those who attend the program. Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event. |